Evidence map›Paper›PMID 42533525›Full record

ArticleFuture oncology (London, England)2026

Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries.

Harshali Patel, Lynn Huynh, Patrick Squires, Jennifer Prescott, Katherine Ryland, Maryaline Catillon, Tracy Guo, Kelvin Tamakloe, Steven Liu, Mei Sheng Duh and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Harshali PatelMerck & Co., Inc., Rahway, NJ, USA.ORCID 0009-0002-6598-1877
Lynn HuynhAnalysis Group, Inc., Boston, MA, USA.ORCID 0000-0003-3110-6775
Patrick SquiresMerck & Co., Inc., Rahway, NJ, USA.ORCID 0009-0003-6819-5764
Jennifer PrescottMerck & Co., Inc., Rahway, NJ, USA.ORCID 0000-0002-5703-8953
Katherine RylandMerck & Co., Inc., Rahway, NJ, USA.ORCID 0009-0001-1749-7880
Maryaline CatillonAnalysis Group, Inc., Boston, MA, USA.ORCID 0000-0002-1360-8133
Tracy GuoAnalysis Group, Inc., Boston, MA, USA.ORCID 0000-0003-4936-7228
Kelvin TamakloeAnalysis Group, Inc., Boston, MA, USA.ORCID 0009-0004-4041-9145
Steven LiuAnalysis Group, Inc., Boston, MA, USA.ORCID 0009-0001-0782-3582
Mei Sheng DuhAnalysis Group, Inc., Boston, MA, USA.ORCID 0000-0001-5035-6687
Monika RautMerck & Co., Inc., Rahway, NJ, USA.ORCID 0009-0000-9538-2934
Craig A PortellDivision of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.ORCID 0000-0002-9487-8345

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven the rarity of marginal zone lymphoma (MZL), real-world data on relapsed/refractory (R/R) MZL are limited.

methodsThis retrospective panel-based chart review study examined patient characteristics and treatment patterns among patients with R/R MZL who received a second or third line (2L or 3L) of therapy between 1 January 2014 and 31 December 2021 in 7 countries. Treatment patterns were summarized overall and by MZL type.

resultsThe study included 526 patients, 513 with 2L and 13 with 3L as index treatment. The median age of 2L patients was 67.0 years. Most patients had stage III or IV disease and intermediate or high-risk prognostic scores. Around 60.0% of the patients had nodal, 22.8% had splenic, and 14.2% had mucosa-associated lymphoid tissue (MALT) MZL. Most patients received chemoimmunotherapy (42.8%), Bruton's tyrosine kinase inhibitors (BTKi; 25.1%), or lenalidomide and rituximab/obinutuzumab (16.3%) in 2L. Treatment patterns varied across subtypes, with notable differences in 2L BTKi use.

conclusionsThese findings suggest variability and limitations in the treatment selection for R/R MZL beyond frontline therapy, with the choice of treatment mostly limited to chemoimmunotherapy and BTKi. This study provides much-needed real-world evidence that can help guide clinical management and the development of novel therapies.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, B-Cell, Marginal ZoneNeoplasm Recurrence, LocalAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective Studiesmarginal zone lymphomapanel-based chart reviewRelapsed/refractoryretrospectivetreatment patterns

Identifiers

PMID42533525
PMCPMC13580472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.